Needham & Company Maintains a 'Hold' on Par Pharmaceutical (PRX); Is Endo (ENDP) the 'Mystery Bidder' Aug 24, 2012 08:05AM
Needham & Company on Endo Pharmaceuticals (ENDP): Watson (WPI) Gains First Generic Lidoderm Approval; A Few Other Issues Too Aug 24, 2012 07:59AM
Needham & Company maintains a 'Strong Buy' on Mylan (MYL); PRX Grossly Undervalued by TGP, MYL/PRX Instead As Strong Combo Jul 20, 2012 08:31AM
Needham & Company Downgrades Par Pharmaceutical (PRX) to Hold Jul 16, 2012 01:59PM
Needham & Company maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Defending Core Fundamentals Despite Setback From Lovaza Litigation May 30, 2012 07:36AM


May 9, 2012 08:14AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Generic Core Delivers; Substantial Upside with Lovaza on Horizon
Apr 20, 2012 09:46AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Healthy Deal with Handa
Feb 29, 2012 09:52AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Strong New Product Launch Cadence & Conservative Pricing Erosion Support Upward Bias
Jan 9, 2012 08:24AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Analyst Day Highlights Strong Generic Fundamentals, Enhanced Capability and Capacity
Jan 6, 2012 11:20AM Needham & Company: Thoughts Heading Into Par Pharmaceutical's (PRX) January 6, Analyst Day; Generics Take Center Stage
Dec 20, 2011 08:01AM Needham & Company: Specialty Pharmaceuticals - 2012 Preview: European Hangover Expected to Ease; Valuations Reflect Fear Not Fact
Nov 3, 2011 08:10AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); 3Q11 Meets Expectations as Key Products Continue Strong Pace
Oct 19, 2011 08:27AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Confirms Purchase of Divested Teva-Cephalon Products for Bargain Price
Oct 10, 2011 08:06AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Positive Outcome for Par as a Result of Teva-Cephalon Merger
Sep 7, 2011 08:38AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Whistleblower Lawsuit Accuses Par of Illegal Drug-Switching Scheme
Jul 26, 2011 09:15AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Threat Finally Emerges on Megace ES; Longer Term Overhang With No Immediate Bite
Jun 30, 2011 08:50AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Zuplenz & Oravig Life Support Terminated; Restructuring Removes Overhang
Jul 19, 2010 07:49AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL) and Par Pharmaceutical (PRX)
Jul 6, 2010 07:39AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Zuplenz Approval Adds Another Product to Strativa Product Portfolio
May 27, 2010 07:56AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Receives Final FDA Approval for Generic Zegerid
Apr 15, 2010 08:01AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Court Invalidates Zegerid Patents; Adding more Visibility and Certainty to a Key Pipeline Opportunity
Sep 25, 2008 07:55AM Needham & Co Initiates Coverage on Drugs - Generic